Subject area |
Cardiology |
More specific subject area |
Anticoagulation for atrial fibrillation |
Type of data |
Table |
How data was acquired |
Administrative claims data |
Data format |
Analyzed |
Experimental factors |
OLDW patients with atrial fibrillation receiving treatment with either warfarin, apixaban, dabigatran, or rivaroxaban |
Experimental features |
Baseline characteristics (age, gender, and CHADs2 score) and event rates (per 100 person years) for ischemic stroke or systemic embolism and major bleeding. |
Data source location |
US administrative claims, previously published international clinical trial data |
Data accessibility |
Individual, patient-level from Optum Labs Data Warehouse is not publically available, but summary data are provided in the tables and in the linked publication [5] (DOI: 10.1016/j.ijcard.2017.07.043). All clinical trial data included have been previously published. |